Diclegis Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting with difficulty filling Diclegis (doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg) prescriptions has become increasingly common in clinical practice. While Diclegis is not formally listed on the FDA drug shortage database as of 2026, real-world access barriers — including inconsistent pharmacy stocking, insurance prior authorization requirements, and high cash costs — are creating significant disruption for pregnant patients managing nausea and vomiting of pregnancy (NVP). This briefing provides a clinical summary of the access landscape and practical prescribing guidance.

Current Availability Status (2026)

Diclegis is not on the FDA Drug Shortage Database or the ASHP shortage list as of March 2026. Generic doxylamine/pyridoxine 10 mg/10 mg delayed-release tablets are available from multiple manufacturers. Access difficulties are driven by:

Limited routine pharmacy stocking (demand-driven ordering only at many locations)

Brand vs. generic stocking variability across pharmacy networks

High retail cash price ($286–$423 for 60 tablets brand-name) causing prescription abandonment

Insurance prior authorization requirements for brand-name Diclegis

Prescribing Strategy: Default to the Generic

The most impactful prescribing change you can make is to specify the generic — doxylamine succinate/pyridoxine hydrochloride delayed-release 10 mg/10 mg — on all new NVP prescriptions unless brand-specific clinical rationale exists. The generic is:

FDA-approved as therapeutically equivalent to brand-name Diclegis

More widely stocked across pharmacy networks

Available for $45–$80 for 60 tablets with GoodRx or SingleCare coupons

Covered at Tier 1–2 on most commercial formularies without prior authorization

Insurance and Prior Authorization Considerations

Most commercial plans cover generic doxylamine/pyridoxine at Tier 1 or Tier 2 without prior authorization. Brand-name Diclegis may be subject to prior authorization and step therapy requirements, with plans typically requiring documented failure or intolerance of the generic.

If your patient requires brand-name Diclegis (e.g., documented tolerability issues with the generic's inactive ingredients), document this clinical rationale thoroughly in the chart before submitting a PA request. Specify:

Date and duration of generic trial (if applicable)

Specific intolerance or inadequate response observed

Why brand-name is medically necessary for this specific patient

Clinical Alternatives If Doxylamine/Pyridoxine Is Unavailable

If both brand and generic are unavailable or not tolerated, ACOG guidelines support the following second-line agents for NVP:

Bonjesta (doxylamine 20 mg/pyridoxine 20 mg ER): Same mechanism, fewer daily tablets. Brand-name only; costs ~$481–$490 for 30 tablets. May reduce adherence barriers for some patients.

Ondansetron (Zofran) 4 mg q8h PRN: Second-line. FDA Pregnancy Category B. Generic ~$10–$30. Avoid in first trimester when possible due to mixed data on cleft palate risk.

Promethazine 12.5–25 mg q4–6h: FDA Pregnancy Category C. Useful for severe nocturnal NVP. Available as tablet, suppository, or IV. Generic ~$5–$20.

Metoclopramide 10 mg TID: FDA Pregnancy Category B. Avoid prolonged use (>12 weeks) due to tardive dyskinesia risk. Second- or third-line only.

38,375+ patients found their medications in stock

38K+

Find Diclegis In Stock Today →

Helping Patients Navigate Access: A Provider Checklist

Prescribe the generic by default (doxylamine/pyridoxine 10 mg/10 mg delayed-release)

Tell patients to use a GoodRx or SingleCare coupon to reduce cost to $45–$80

Direct patients to medfinder.com/providers to locate pharmacies with stock

Consider 90-day mail-order for patients who have confirmed the medication works for them

Refer uninsured patients to Duchesnay USA's patient assistance program

Final Clinical Note

Diclegis/doxylamine-pyridoxine remains the ACOG-recommended first-line pharmacotherapy for NVP and carries FDA Pregnancy Category A — the safest classification available for medications used in pregnancy. The access challenges are real but solvable with the right information. medfinder for Providers can help your patients locate pharmacies with stock in real time. For a step-by-step guide to helping patients fill this prescription, see How to Help Your Patients Find Diclegis in Stock.